Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Other antiallergic agents,
ATC code: R01AC01.
The active component of Cromo-COMOD nasal spray is sodium cromoglicate, which has the property of inhibiting the release of transfer substances from the so-called mast cells. This prevents a hypersensitivity reaction. Cromo-COMOD nasal spray is administered to prevent these hypersensitivity reactions. Contrary to other nasal cold and hay fever medications, it is possible that the Symptoms only disappear after 2 or 3 weeks.
Cromo-COMOD nasal spray is therefore not suitable for acute treatment.
This product contains no preservatives and is therefore also suitable for patients who have been shown to be hypersensitive to preservatives that may occur in this type of products.

Pharmacokinetic Properties

5.2 Pharmacokinetic properties
Approximately 7% of the administered dose is absorbed through the nasal mucosa.
The majority of the dose is swallowed and eliminated, almost unchanged, via the gastrointestinal tract, as absorption from this is low. Systematically absorbed sodium cromoglicate is reversibly bound to plasma proteins (up to ca. 65%) and is not metabolised, but excreted unchanged in bile and urine in roughly equal proportions. The drug is rapidly cleared from plasma (in a study, plasma clearance after intravenous administration was approximately 8 ml/min/kg, and plasma elimination half-life approximately 1 hour). No accumulation occurs.